Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-09

Study Completion Date

2017-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy

NCT02809911

Painful Peripheral Diabetic Neuropathy

COMPLETED NA

Nociceptive Pain Fiber Response

NCT02696070

Painful Peripheral Diabetic Neuropathy

COMPLETED NA

HTEMS Treatment of Diabetic Polyneuropathy

NCT04593992

Diabetic Polyneuropathy

COMPLETED NA

Treatment of Painful Diabetic Neuropathy With Photon Stimulation

NCT00539175

Diabetic Neuropathy, Painful Diabetic Neuralgia Diabetic Polyneuropathy +1 more

COMPLETED NA

Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy

NCT00337324

Painful Diabetic Neuropathy

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multi-center, sham-controlled, double-blind, enriched enrollment, randomized withdrawal clinical trial conducted on subjects with bilateral symmetrical diabetic peripheral neuropathy. Eligible subjects will include those between 22 and 80 years of age with Type 1 or Type 2 diabetes having persistent pain, numbness, tingling, or burning in both feet despite treatment. Eligible subjects will receive two active treatment devices (one for each foot, to allow simultaneous treatment) and treat at home, twice daily for 60 days after which they will return to the clinic at Day 61 for a response assessment. Subjects that are determined to be responders at Day 61 (subjects that achieve a 1-point decrease in the average pain score over the last 24 hours using the Numeric Pain Rating Scale (NPRS)) will be randomized 1:1 to either active treatment or inactive sham devices and will continue treating through Day 120. Subjects that are determined to be non-responders at Day 61 will continue treating with the active devices given at enrollment and will return to the clinic at Day 75 and Day 91 for a response assessment. If a subject is determined to be a responder at Day 75, they will be randomized 1:1 to receive either active treatment or inactive sham and will continue treating through Day 120. If a subject is determined to be a responder at Day 91, they will be randomized 1:1 to receive either active treatment or sham and will continue to treat through Day 120. If a subject continues to be a non-responder at Day 91 they will be terminated from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects deemed "responders" after active treatment will be randomized in a 1:1 ratio to either active treatment or a sham device.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Sham devices will look identical to active devices. This is a double-blind study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Group

Treatment with active Provant Therapy System

Group Type EXPERIMENTAL

Active Provant Therapy System

Intervention Type DEVICE

Treatment with active Provant Therapy System

Sham Group

Treatment with Inactive (sham) Provant Therapy System

Group Type SHAM_COMPARATOR

Inactive (sham) Provant Therapy System

Intervention Type DEVICE

Treatment with Inactive (sham) Provant Therapy System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active Provant Therapy System

Treatment with active Provant Therapy System

Intervention Type DEVICE

Inactive (sham) Provant Therapy System

Treatment with Inactive (sham) Provant Therapy System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject age is greater than or equal to 22 years and less than 80 years of age.
2. Subject has documented Type 1 or Type 2 diabetes mellitus (receiving insulin, diet controlled, or taking parenteral hypoglycemic agents)
3. Subject is on a stable antidiabetic regimen (medication and/or diet) to control their diabetes for at least 30 days prior to Screening.
4. Subject has an HbA1c \<10% at Screening or within 2 months of Screening.
5. Subject has daily pain attributed to bilateral symmetrical Diabetic Peripheral Neuropathy with numbness, tingling, and/or burning based on clinical judgement for at least 6 months prior to screening.
6. Subject's pain or discomfort from DPN is identifiable.
7. Subject is in pain Phase 2, 3, or 4 as per the Phasing of Neuropathy Scale.
8. Subjects average pain over the last 24 hours is ≥3 based on the 11-point Numeric Pain Rating Scale (NPRS) at the Screening Visit.
9. Subject has adequate lower extremity pulse in both feet and no intermittent claudication.
10. Subject is able to ambulate independently without assistive devices.
11. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol.
12. Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agrees to practice) an effective method of birth control if they are sexually active for the duration of the study (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).

Exclusion Criteria

1. Subject is in pain Phase 1 or 5 as per the Phasing of Neuropathy Scale.
2. Subject has an active, open ulcer on the lower extremities.
3. Subject has peripheral vascular disease defined as absence of more than one foot pulse per foot and/or ABI \<0.8 and \>1.4 and/or history of angioplasty or peripheral bypass surgery within 6 months of the Screening Visit.
4. Subject has venous insufficiency as classified by the Venous Insufficiency Classification System of grade C6.
5. Subject has undergone nerve decompression surgery on the lower extremities.
6. Subject has a history of previous kidney, pancreas, cardiac transplantation, or severe renal disease.
7. Subject has been diagnosed with non-diabetic chronic inflammatory neuropathic disease (e.g. end stage renal disease, hepatitis C, chemotherapy induced neuropathy, known connective tissue disease, systemic lupus).
8. Subject has peripheral vascular disease requiring revascularization of lower limb or amputation or evidence of ulcer amputation.
9. Subject has clinically significant cardiovascular disease within 6 months prior to screening (unstable or poorly controlled hypertension, transient ischemic attack, MI, unstable angina, arrhythmia, any heart surgery, stent placement, heart disease).
10. Subject has a history of any uncontrolled medical illness that in the Investigators judgment places the subject at unacceptable risk for receipt of PEMF therapy.
11. Subject requires or anticipates the need for surgery of any type or travel during the treatment period.
12. Subject has a total foot depth (most inferior aspect of the medial malleolus to the plantar aspect of the foot when residing on a treatment pad) of \>8 cm.
13. Subject has received any investigational drug or device within 30 days prior to the Screening Visit or within 6 weeks prior to the Screening Visit for long acting lidocaine injection products.
14. Subject has used systemic corticosteroids within 3 months of the Screening Visit.
15. Subject has a history of malignancy within the past 5 years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area and/or localized in situ carcinoma of the cervix.
16. Subject has a serious psychosocial co-morbidity.
17. Subject has a history of drug or alcohol abuse, as confirmed by urine drug screen, within one year prior to the Screening Visit.
18. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
19. Subject is currently pregnant or planning on becoming pregnant prior to Day 121.
20. Subject has previously treated with PROVANT® Therapy System within 60 days on the lower extremity.
21. Subject is unwilling or unable to follow study instructions or comply with the treatment regimen, diary documentation, and study visits.
22. Subject has pain from any other source that can confuse the assessment of the pain associated with DPN.
23. Subject has a clinically significant foot deformity (Charcot's syndrome or club foot).
24. Subject has received nerve blocks for neuropathic pain within 4 weeks of the Screening Visit.
25. Subject has been diagnosed with mononeuropathy.
26. Subject has a skin condition that could alter their sensation.
27. Subject has had a previous surgery to the spine or lower extremity with residual symptoms of pain or difficulty with movement.
28. Subject has moderate or severe arthropathy (RA, OA, Gout) that causes discomfort during casual walking or stair climbing.

Minimum Eligible Age

22 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No